使用PHQ-9进行抑郁症随访监测:一项开放集群随机对照试验
该研究在141家全科诊所开展开放集群随机对照试验,招募新发抑郁发作成人,干预组使用PHQ-9并进行患者反馈。结果显示12周时BDI-II评分无显著差异,但26周时EQ-5D-5L生活质量评分在干预组更高,抑郁结局的临床显著差异不能排除。
要点
- 12周时干预组与对照组BDI-II评分无显著差异(均差-0.46;95%CI -2.16至1.26)。
- 26周时干预组EQ-5D-5L生活质量评分更高(调整均差0.053;95%CI 0.013至0.093)。
- 符合方案分析中,有记录随访PHQ-9的干预组患者抗抑郁药使用和心理健康接触显著更多(P=0.025和P=0.010)。
核心结论
- 未发现PHQ-9监测在12周时改善抑郁结局的证据。
- 26周时可能获益的发现需重复验证,并探究可能机制。
研究设计与样本
- 开放集群随机对照试验,在141家全科诊所开展。
- 招募新发抑郁发作成人,排除痴呆、精神病、物质滥用和自杀风险者。
- 干预组302例,对照组227例;12周随访率分别为84.1%和87.7%。
主要发现
- 12周BDI-II评分无显著差异(均差-0.46;95%CI -2.16至1.26)。
- 26周EQ-5D-5L生活质量评分干预组更高(调整均差0.053;95%CI 0.013至0.093)。
- 社会功能、不良事件和满意度无显著差异。
- 符合方案分析中有记录随访PHQ-9的干预组患者抗抑郁药使用和心理健康接触显著更多(P=0.025和P=0.010)。
临床怎么用
- 全科医生可考虑使用PHQ-9进行抑郁随访监测,但需注意当前证据未显示12周抑郁结局改善。
- 监测可能对26周生活质量有潜在益处,但需进一步验证。
局限性
- 干预组仅40.9%患者有全科医生记录的随访PHQ-9。
- 26周抑郁的临床显著差异不能排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcome monitoring of depression treatment is recommended but there is a lack of evidence on patient benefit in primary care. AIM: To test monitoring depression using the Patient Health Questionnaire (PHQ-9) with patient feedback. DESIGN AND SETTING: An open cluster-randomised controlled trial was undertaken in 141 group practices. METHOD: Adults with new depressive episodes were recruited through record searches and opportunistically. The exclusion criteria were as follows: dementia; psychosis; substance misuse; and suicide risk. The PHQ-9 was administered soon after diagnosis, and 10-35 days later. The primary outcome was the Beck Depression Inventory (BDI-II) score at 12 weeks. The secondary outcomes were as follows: BDI-II at 26 weeks; Work and Social Adjustment Scale (WSAS) and EuroQol EQ-5D-5L quality of life at 12 and 26 weeks; antidepressant treatment; mental health and social service contacts; adverse events, and Medical Interview Satisfaction Scale (MISS) over 26 weeks. RESULTS: In total, 302 patients were recruited to the intervention arm and 227 to the controls. At 12 weeks, 254 (84.1%) and 199 (87.7%) were followed-up, respectively. Only 40.9% of patients in the intervention had a GP follow-up PHQ-9 recorded. There was no significant difference in BDI-II score at 12 weeks (mean difference -0.46; 95% confidence interval [CI] = -2.16 to 1.26; adjusted for baseline depression, baseline anxiety, sociodemographic factors, and clustering by practice). EQ-5D-5L quality-of-life scores were higher in the intervention arm at 26 weeks (adjusted mean difference 0.053; 95% CI = 0.013 to 0.093. A clinically significant difference in depression at 26 weeks could not be ruled out. No significant differences were found in social functioning, adverse events, or satisfaction. In a per-protocol analysis, antidepressant use and mental health contacts were significantly greater in patients in the intervention arm with a recorded follow-up PHQ-9 (P = 0.025 and P = 0.010, respectively). CONCLUSION: No evidence was found of improved depression outcome at 12 weeks from monitoring. The findings of possible benefits over 26 weeks warrant replication, investigating possible mechanisms, preferably with automated delivery of monitoring and more instructive feedback.
引用
- Kendrick T, Dowrick C, Lewis G, et al. Depression follow-up monitoring with the PHQ-9: an open cluster-randomised controlled trial. Br J Gen Pract. 2024. PMID: 38408790. doi:10.3399/BJGP.2023.0539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。